
PC25479A Information Disclosure Statement For Appln. No. 10/688,648 Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents, PO Box 1450, Alexandria,





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

TERO AHOLA

Serial No.: 10/688,648

Confirmation No.: 1230

Filed: October 17, 2003

For: PHARMACEUTICAL

Group Art Unit: 1617

Examiner: Not Yet Assigned

Honorable Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

The Information Disclosure Statement submitted herewith is being filed within three
months of the filing date of a national application other than a continued prosecution
application under § 1.53(d); within three months of the date of entry of the national stage
as set forth in § 1.491 in an international application; before the mailing of a first Office
Action on the merits; or before the mailing of a first Office Action after the filing of a
request for continued examination under § 1.114.

37 CFR § 1.97(b)

37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

04/05/2004 WABRHAM1 00000096 500329 10688648

01 FC:1806 180.00 DA

1

Applicant requests that the Examiner consider the following copending app				e following copending applications:			
		Application Serial No.	Filing Date				
		Copies of these copending applications are enclosed.					
\boxtimes	Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.						
		This application is a continuation, divisional or continuation-in-part of Serial No. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.					
		This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).					
	Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.						
under 3	7 C.F.R	oner is hereby authorized to a. § 1.17(p), or credit any of of this form is enclosed.	o charge any foverpayment,	ee deficiency, including any fee required to Deposit Account Number 500329. A			
				Respectfully submitted,			
Date: _	Ma	rch 30, 2004		Keith D. Hutchinson Attorney For Applicant Registration No. 43,687			

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive San Diego, California 92121 Phone: (858) 526-4608 Fax: (858) 678-8233

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

· · · ·

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/688,648	
Filing Date	October 17, 2003	
First Named Inventor	Tero Ahola	
Art Unit	TBA	
Examiner Name	TBA	
Attorney Docket Number	PC25479A	

PACEMAN.	U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	Cite No. 1	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,159,939A	12-12-2000	Jeffrey Glenn	
	AB	2002/15183A1	10-17-2002	Assa Weinberg	

Foreign Patent Document Country Code ³ Number ⁴ Kind	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	17
Code ⁵ (if known)	MM-DD-YYYY	or often bodament	Relevant Passages or Relevant Figures Appear	
WO 02/088338A	11-07-2002	Centre National De La Recherche Scientifique	·	
WO 02/067853A	09-06-2002	Pro-Biochem, LLC		
			WO 02/088338A 11-07-2002 Recherche Scientifique	WO 02/088338A 11-07-2002 Recherche Scientifique

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AE	DAVIGNON, et al., "Mecanismes d'action des statines et leurs effets pleiotropes," <i>Annales d'Endocrinologie</i> , 2001, 101-112, Vol. 62, No. 1.		
···				

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.